Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trial

Pharmacogenomics

Volumn 9, Issue 3, 2008, Pages 289-301

  Lavedan, Christian ^a   Volpi, Simona ^a   Polymeropoulos, Mihael H ^a   Wolfgang, Curt D ^a  

^a Vanda Pharmaceuticals Inc   (United States)

Author keywords

CNTF; Iloperidone; Pharmacogenetics; Polymorphism; Schizophrenia

Indexed keywords

CILIARY NEUROTROPHIC FACTOR; ILOPERIDONE; PLACEBO; ZIPRASIDONE; ISOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PIPERIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA EXTRACTION; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPROTECTION; NULL ALLELE; PHARMACOGENETICS; POSITIVE AND NEGATIVE SYNDROME SCALE; PROTEIN FUNCTION; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; UNSPECIFIED SIDE EFFECT; GENETICS; PSYCHOLOGY; RACE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTIPSYCHOTIC AGENTS; CILIARY NEUROTROPHIC FACTOR; CONTINENTAL POPULATION GROUPS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOXAZOLES; MALE; PIPERIDINES; PLACEBOS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 40849110964     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.3.289     Document Type: Article

References (39)

1. Kane JM, Malhotra A: The future of pharmacotherapy for schizophrenia. World Psychiatry 2(2), 81-86 (2003).
2. Arranz MJ, Collier DA, Munro J et al.: Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci Lett. 217(2-3), 177-178 (1996).
3. Arranz M, Collier D, Sodhi M et al.: Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 346(8970), 291-282 (1995).
4. Hwang R, Shinkai T, Deluca V et al.: Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment. Eur. Neuropsychopharmacol. 16(4), 248-259 (2006).
5. Lane HY, Lin CC, Huang CH, Chang YC, Hsu SK, Chang WH: Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders. Schizophr. Res. 67(1), 63-70 (2004).
6. Lane HY, Hsu SK, Liu YC, Chang YC, Huang CH, Chang WH: Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. J. Clin. Psychopharmacol. 25(1), 6-11 (2005).
7. Sendtner M, Carroll P, Holtmann B, Hughes RA, Thoenen H: Ciliary neurotrophic factor. J. Neurobiol. 25(11), 1436-1453 (1994).
8. Stankoff B, Aigrot MS, Noel F, Wattilliaux A, Zalc B, Lubetzki C: Ciliary neurotrophic factor (CNTF) enhances myelin formation: a novel role for CNTF and CNTF-related molecules. J. Neurosci. 22(21), 9221-9227 (2002).
9. Dziermis S, Habecker BA: Cytokine suppression of dopamine-β-hydroxylase by extracellular signal-regulated kinase-dependent and -independent pathways. J. Biol. Chem. 278(18), 15897-15904 (2003).
10. Magal E, Burnham P Varon S, Louis JC: Convergent regulation by ciliary neurotrophic factor and dopamine of tyrosine hydroxylase expression in cultures of rat substantia nigra. Neuroscience 52(4), 867-881 (1993).
11. Rudge JS, Eaton MJ, Mather P, Lindsay RM, Whittemore SR: CNT9 induces raphe neuronal precursors to switch from a serotonergic to a cholinergic phenotype in vitro. Mol. Cell. Neurosci. 7(3), 204-221 (1996).
12. Emerich DF, Lindner MD, Winn SR, Chen EY, Frydel BR, Kordower JH: Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease. J. Neurosci. 16(16), 5168-5181 (1996).
13. Hagg T, Varon S: Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo. Proc. Natl Acad Sci. USA 90(13), 6315-6319 (1993).
14. Masu Y, Wolf E, Holtmann B, Sendtner M, Brem G, Thoenen H: Disruption of the CNTF gene results in motor neuron degeneration. Nature 365(6441), 27-32 (1993).
15. Tolosano E, Cutufia MA, Hirsch E et al.: Ciliary neurotrophic factor constitutively expressed in the nervous system of transgenic mice protects embryonic dorsal root ganglion neurons from apoptosis. Eur. J. Neurosci. 8(3), 521-529 (1996).
16. Siegel SG, Patton B, English AW: Ciliary neurotrophic factor is required for motoneuron sprouting. Exp. Neurol. 166(2), 205-212 (2000).
17. Naumann T, Steup A, Schnell O et al.: Altered neuronal responses and regulation of neurotrophic proteins in the medial septum following fimbria-fornix transection in. Eur. J. Neurosci. 24(8), 2223-2232 (2006).
18. Vostrikov V, Orlovskaya D, Uranova N: Deficit of pericapillary oligodendrocytes in the prefrontal cortex in schizophrenia. World J. Biol. Psychiatry 1-9 (2007).
19. Vostrikov VM, Uranova NA, Orlovskaya DD: Deficit of perineuronal oligodendrocytes in the prefrontal cortex in schizophrenia and mood disorders. Schizophr. Res. 94(1-3), 273-280 (2007).
20. Uranova NA, Vostrikov VM, Vikhreva OV, Zimina IS, Kolomeets NS, Orlovskaya DD: The role of oligodendrocyte pathology in schizophrenia. Int. J. Neumosychopharmacol. 10(4), 537-545 (2007).
21. Galter D, Unsicker K: Regulation of the transmitter phenotype of rostral and caudal groups of cultured serotonergic raphe neurons. Neuroscience 88(2), 549-559 (1999).
22. Takahashi R, Yokoji H, Misawa H, Hayashi M, Hu J, Deguchi T. A null mutation in the human CNTF gene is not causally related to neurological diseases. Nat. Genet. 7(1), 79-84 (1994).
23. Roth SM, Schrager MA, Ferrell RE et al.: CNTF genotype is associated with muscular strength and quality in humans across the adult age span. J. Appl. Physiol. 90(4), 1205-1210 (2001).
24. Sakai T, Sasaki T, Tatsumi M, Kunugi H, Hattori M, Nanko S: Schizophrenia and the ciliary neurotrophic factor (CNTF) gene: no evidence for association. Psychiatry Res. 71(1), 7-10 (1997).
25. Tanaka Y, Ujike H, Fujiwara Y et al.: Schizophrenic psychoses and the CNTFnull mutation. Neuroreport 9(6), 981-983 (1998).
26. Lin PY, Tsai G: Meta-analyses of the association between genetic polymorphisms of neurotrophic factors and schizophrenia. Schizophr. Res. 71(2-3), 358-360 (2004).
27. Thome J, Durany N, Harsanyi A et al.: A null mutation allele in the CNTF gene and schizophrenic psychoses. Neuroreport 7(8), 1413-1416 (1996).
28. Nishiyama J, Tochigi M, Itoh S et al.: No association between the CNTF null mutation and schizophrenia or personality. Psychiatr. Genet. 16(5), 217-219 (2006).
29. Gelernter J, van Dyk C, van Kammen DP et al.: Ciliary neurotrophic factor null allele frequencies in schizophrenia, affective disorders, and Alzheimer's disease. Am. J. Med. Genet. 74(5), 497-500 (1997).
30. Jain KK: An assessment of iloperidone for the treatment of schizophrenia. Expert Opin. Investig. Drugs. 9(12), 2935-2943 (2000).
31. Cutler AJ, Kalali AH, Weiden P, Hamilton J, Wolfgang CD: Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J. Clin. Psychopharmacol. (2008) (In press).
32. Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophir. Bull. 13(2), 261-276 (1987).
33. American Psychiatric Association: Diagnostic and statistical manual of mental disorders, text revision: DSM-IV-TR. 4th Edition. American Psychiatric Association, Washington DC, USA (2000).
34. Lindblad-Toh K, Winchester E, Daly MJ et al.: Large-scale discovery and genotyping of single-nucleotide polymorphisms in the mouse. Nat. Genet. 24(4), 381-386 (2000).
35. Welge JA, Keck PE Jr: Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression. Psychopharmacology (Berl.). 166(1), 1-10 (2003).
36. Stefano CB, Fricchione GL, Slingsby BT. Benson H: The placebo effect and relaxation response: neural processes and their coupling to constitutive nitric oxide. Brain Res. Brain Res. Rev. 35 (1), 1-19 (2001).
37. Zhou X, Espey MG, Chen JX et al.: Inhibitory effects of nitric oxide and nitrosative stress on dopamine-β-hydroxylase. J. Biol. Chem. 275 (28), 21241-21246 (2000).
38. Stefano GB, Salzet B, Rialas CM et al.: Morphine and anandamide-stimulated nitric oxide production inhibits presynaptic dopamine release. Brain Res. 763(1), 63-68 (1997).
39. Kaur N, Lu B, Monroe RK, Ward SM, Halvorsen SW: Inducers of oxidative stress block ciliary neurotrophic factor activation of Jak/STAT signaling in neurons. J. Neurochem. 92(6), 1521-1530 (2005).